Publicacions en què col·labora amb J. R. González Porras (11)

2022

  1. Current status of diagnosis and treatment of heparin-induced thrombocytopenia (HIT)

    Medicina Clinica, Vol. 158, Núm. 2, pp. 82-89

  2. Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH

    Clinical and Translational Oncology, Vol. 24, Núm. 5, pp. 770-783

2019

  1. Identification of 58 mutations (26 Novel) in 94 of 109 symptomatic Spanish probands with protein C deficiency

    Thrombosis and Haemostasis, Vol. 119, Núm. 9, pp. 1409-1418

2018

  1. Hemostasia y trombosis: manual práctico

    Arán

2017

  1. Clinical perspectives on the management of bleeding in patients on oral anticoagulants: The DECOVER Study (DElphi Consensus on oral COagulation and therapy action reVERsa

    Emergencias, Vol. 29, Núm. 1, pp. 18-26

2016

  1. Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study

    European Journal of Haematology, Vol. 97, Núm. 2, pp. 128-136

  2. Short Leukocyte Telomere Length Is Associated with Cardioembolic Stroke Risk in Patients with Atrial Fibrillation

    Stroke, Vol. 47, Núm. 3, pp. 863-865

2008

  1. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms

    Haematologica, Vol. 93, Núm. 5, pp. 729-734

2007

  1. Antithrombin Cambridge II (A384S): An underestimated genetic risk factor for venous thrombosis

    Blood, Vol. 109, Núm. 10, pp. 4258-4263

2006

  1. A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis

    Blood, Vol. 108, Núm. 1, pp. 177-183

2004

  1. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma

    Leukemia, Vol. 18, Núm. 4, pp. 856-863